Project Grant R01AA031723
Award Date 9/20/25
Completion Date 8/31/30
Dollars Obligated $672K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the Department of Health and Human Services, awarded a $3,227,517 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Colorado-Denver. The grant, awarded on September 20, 2025 with a completion date of August 31, 2029, is funding research to investigate the effects of full-spectrum cannabidiol (CBD) on alcohol consumption and alcohol use disorder phenotypes. The goal is to identify safe and...
- This Project Grant award, totaling $268,470.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The project will study the impacts of recent state-level laws legalizing medical cannabidiol (CBD) on substance use, including CBD use, opioid use, and alcohol use, as well as associated overdose rates. The research team, led by the RAND Corporation, will also collect and publish data on CBD dispensary locations and...
- This federal Project Grant award of $123,045.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) grant program. The award supports research to investigate interactions between the alcohol and cannabinoid systems in the context of pain and alcohol use disorder (AUD). The project aims to examine the potential analgesic effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, on pain...
- This $232,625 project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to assess the potential of pregnenolone, a signaling specific negative allosteric modulator (NAM) of the CB1 cannabinoid receptor, to reverse symptoms of cannabis intoxication in humans. The study will utilize a within-subjects, double-blind, placebo-controlled design to evaluate the ability of two different doses of pregnenolone (250 mg and...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $686,692 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina. The grant will fund an 8-week clinical trial to assess the prospective changes in patient-reported and objective functioning following reduction of cannabis use among adults with cannabis use disorder. The trial will evaluate the benefits of cannabis harm...
- This federal Project Grant award, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), is focused on evaluating cannabidiol (CBD) as a "cognitive enhancer" to improve the efficacy of cognitive behavioral therapy (CBT) for treating generalized anxiety disorder (GAD). The $1,715,387 award will fund a study to test the hypothesis that the combination of CBD and CBT will result in greater reductions in GAD symptom...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...